Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19781551 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL6296539 | 0.81 | GSK3B (0.39) | SMN1; SMN2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL31753473 | 0.81 | NPC1 (0.61) | SMN1; SMN2ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL4907676 | 0.80 | GRM5 (0.50) | SMN1; SMN2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL19937659 | 0.80 | RAF1 (0.49) | RAF1GSK3BDYRK1AMAPK14CYP17A1 | |
| SCHEMBL28055517 | 0.80 | RAF1 (0.49) | SMN1; SMN2ALDH1A1NPC1RAB9ARAF1 | |
| SCHEMBL13472630 | 0.79 | NPC1 (0.63) | SMN1; SMN2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL31341001 | 0.79 | GSK3B (0.40) | SMN1; SMN2ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL15885857 | 0.79 | IRAK4 (0.55) | GSK3BDYRK1A | |
| SCHEMBL16699185 | 0.79 | KDM4E (0.49) | SMN1; SMN2ALDH1A1LMNAKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114127058-B | Heterocyclic compound, pharmaceutical composition and application thereof | 深圳国顺康医药科技有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11623922-B2 | Compounds | INFLAZOME LIMITED (IE) | 2023-04-11 | — | — | US | disclosed |
| CN-112533913-A | Novel compounds | 英夫拉索姆有限公司 | 2021-03-19 | — | — | CN | disclosed |
| WO-2021000957-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 北京国鸿生物医药科技有限公司 | 2021-01-07 | — | — | WO | disclosed |
| US-20200392138-A1 | PESTICIDALLY ACTIVE MESOIONIC HETEROCYCLIC COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2020-12-17 | — | — | US | disclosed |
| US-10829484-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200331886-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-22 | — | — | US | disclosed |
| CN-111511721-A | Pesticidally active mesoionic heterocyclic compounds | 先正达参股股份有限公司 | 2020-08-07 | — | — | CN | disclosed |
| WO-2019115404-A1 | PESTICIDALLY ACTIVE MESOIONIC HETEROCYCLIC COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019068772-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-04-11 | — | — | WO | disclosed |
| CN-106459045-A | Heterocyclic kinase inhibitors | 艾伯维公司 | 2017-02-22 | — | — | CN | disclosed |
| WO-2017019804-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| US-20170029413-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-02-02 | — | — | US | disclosed |
| WO-2015050989-A2 | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CS THERAPEUTICS INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| US-8293757-B2 | 5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2012-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11623922-B2 | Compounds | NLRP3, NOD1, NLRP1 | SMN1; SMN2 3895/4885ALDH1A1 616/4885LMNA 452/4885 |
| US-20200331886-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | SMN1; SMN2 4071/4885ALDH1A1 520/4885LMNA 511/4885 |
| US-20200392138-A1 | PESTICIDALLY ACTIVE MESOIONIC HETEROCYCLIC COMPOUNDS | DDT, ACHE, MNS1 | SMN1; SMN2 487/4885ALDH1A1 891/4885LMNA 2510/4885 |
| US-20170029413-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K11, PRKAR2B, MAP3K13 | SMN1; SMN2 2111/4885ALDH1A1 4034/4885LMNA 1234/4885 |
| US-10829484-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K11, PRKAR2B, MAP3K13 | SMN1; SMN2 2111/4885ALDH1A1 4034/4885LMNA 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.